ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
93.00 ^USD	+16.13%		-38.24%	-48.96%

Feb. 12	Sector Update: Health Care Stocks Higher Thursday Afternoon	MT
Feb. 12	Top Midday Decliners	MT

BofA Securities Downgrades ICON to Neutral From Buy

Published on 12/15/2025 at 07:24 am EST

MT Newswires

Latest news about ICON Public Limited Company

Feb. 12	Sector Update: Health Care Stocks Higher Thursday Afternoon	MT
Feb. 12	Top Midday Decliners	MT
Feb. 12	Top Midday Stories: ICON Launches Internal Probe Into Accounting Practices; AppLovin Shares Fall Despite Strong Q4 Earnings, Guidance	MT
Feb. 12	ICON Shares Slump Amid Internal Investigation	MT
Feb. 12	Top Premarket Decliners	MT
Jan. 27	ICON?s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership	CI
Jan. 08	Peace Was Cheaper
Jan. 08	Truist Downgrades ICON PLC to Hold From Buy, Trims Price Target to $222 From $231	MT
Jan. 08	Analyst recommendations: Alphabet, Chubb, Ford, Stellantis, The Gap…
Dec. 15	BofA Securities Downgrades ICON to Neutral From Buy	MT
Dec. 09	ICON plc Releases Findings from Two Biotech Sector Survey	CI
Dec. 02	Icon survey reveals increasing clinical trial startup delays	RE
Dec. 02	Icon plc Announces Results of Its Latest Industry Survey	CI
Nov. 20	ICON Public Limited Company Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 09:00 AM
Nov. 13	BMO Capital Initiates Coverage on ICON With Market Perform Rating, $175 Price Target	MT

Chart ICON Public Limited Company

Duration

Period

ICLR: Dynamic Chart

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

39,800

Sector

Biotechnology & Medical Research

Calendar

Feb. 24 - Q4 2025 Earnings Release (Projected)

More about the company